Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Vanda To Pay Eli Lilly Up To $100 Million In Drug Development Agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/16/2012 | 01:50pm CEST

Vanda Pharmaceuticals Inc. (>> Vanda Pharmaceuticals Inc.) agreed to pay Eli Lilly Co. (LLY) up to $100 million for the exclusive right to develop a drug that has shown some promise as a treatment for alcohol addiction.

Under its deal with Lilly, the biopharmaceutical company will pay a $1 million initial license fee and take responsibility for all development costs of the VLY-686 drug.

Lilly is also eligible to receive additional payments based upon certain milestones and royalties on sales. These milestones include $4 million for milestones achieved prior to a new drug application and up to $95 million for future regulatory approval and sales milestones.

Vanda, which focuses on treatments for central nervous system disorders, noted that prior research of VLY-686 has focused on its potential as a novel therapeutic for individuals struggling with dependence on alcohol.

"The licensing of VLY-686 is an important milestone for Vanda, as we continue to realize our vision of developing treatments to address unmet medical needs," said Chief Executive Mihael H. Polymeropoulos.

Vanda in February reported it swung to a loss in the fourth quarter as increased expenses outweighed higher revenue for the period.

Shares closed Friday at $4.49 and were inactive in premarket trade. The stock has slumped 42% over the past year.

-By Mia Lamar, Dow Jones Newswires; 212-416-3207; mia.lamar@dowjones.com

Stocks mentioned in the article : Vanda Pharmaceuticals Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VANDA PHARMACEUTICALS INC.
03/13 VANDA PHARMACEUTICALS INC. (NASDAQ : VNDA) Files An 8-K Departure of Directors o..
03/13 VANDA PHARMACEUTICALS INC. : Change in Directors or Principal Officers (form 8-K..
03/06 VANDA PHARMACEUTICALS INC. : Change in Directors or Principal Officers (form 8-K..
03/06 VANDA PHARMACEUTICALS : Announces Participation at March 2017 Investor Conferenc..
03/03 VANDA PHARMACEUTICALS : Federal Contracts Awarded to Companies in District of Co..
03/03 VANDA PHARMACEUTICALS : CONTRACT AWARD - 65-- Vanda Pharmaceuticals 03-01-2017-0..
03/03 VANDA PHARMACEUTICALS : $1.96 Million Federal Contract Awarded to Vanda Pharmace..
02/17 VANDA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
02/15 VANDA PHARMACEUTICALS : reports 4Q loss
02/15 VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Fina..
More news
Sector news : Bio Therapeutic Drugs
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/22 Vanda Pharmaceuticals (VNDA) Presents At Oppenheimer 27th Annual Healthcare C..
03/08 Vanda Pharmaceuticals (VNDA) Presents At Cowen and Company 37th Annual Health..
03/02 VANDA : Investing For Growth
02/15 Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q4 2016 Results - ..
02/15 Vanda Pharmaceuticals beats by $0.08, misses on revenue
Advertisement
Financials ($)
Sales 2017 169 M
EBIT 2017 -27,9 M
Net income 2017 -21,3 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 3,79x
Capi. / Sales 2018 3,13x
Capitalization 639 M
More Financials
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Full-screen chart
Technical analysis trends VANDA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 22,3 $
Spread / Average Target 55%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Vincent J. Milano Independent Director
Michael F. Cola Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS ..-9.72%639
AMGEN, INC.12.79%121 448
CELGENE CORPORATION7.87%97 137
GILEAD SCIENCES, INC.-5.74%88 227
REGENERON PHARMACEUTIC..4.52%40 701
ACTELION LTD24.40%29 848
More Results